Diverse roles of SIRT1 in cancer biology and lipid metabolism

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2015, Pages 950-965

  Simmons, Glenn E ^a   Pruitt, Wendy M ^b   Pruitt, Kevin ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Fatty acid; Lipids; Lipolysis; Metabolism; SIRT1; Sirtuin; Steatosis; Sterol regulatory element binding protein (SREBP)

Indexed keywords

CHOLESTEROL; ESTROGEN; FATTY ACID BINDING PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; HISTONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NONHISTONE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOTRANSFERASE; SIRTUIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; FATTY ACID; FOXO1 PROTEIN, HUMAN; PPARGC1A PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

CANCER CELL; CELLULAR STRESS RESPONSE; DEACETYLATION; DOWN REGULATION; ENZYME REGULATION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; HUMAN; LIPID METABOLISM; MULTIDRUG RESISTANCE; NEOPLASM; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; BIOSYNTHESIS; ENERGY METABOLISM; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ENERGY METABOLISM; FATTY ACIDS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LIPID METABOLISM; NEOPLASMS; PPAR GAMMA; PROTEIN-SERINE-THREONINE KINASES; SIRTUIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTORS;

EID: 84920527600     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16010950     Document Type: Review

References (87)

1. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat. Rev. Genet. 2009, 10, 32–42.
2. Krusche, C.A.; Wulfing, P.; Kersting, C.; Vloet, A.; Bocker, W.; Kiesel, L.; Beier, H.M.; Alfer, J. Histone deacetylase-1 and -3 protein expression in human breast cancer: A tissue microarray analysis. Breast Cancer Res. Treat. 2005, 90, 15–23.
3. Weichert, W.; Roske, A.; Niesporek, S.; Noske, A.; Buckendahl, A.C.; Dietel, M.; Gekeler, V.; Boehm, M.; Beckers, T.; Denkert, C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 2008, 14, 1669–1677.
4. Powell, M.J.; Casimiro, M.C.; Cordon-Cardo, C.; He, X.; Yeow, W.S.; Wang, C.; McCue, P.A.; McBurney, M.W.; Pestell, R.G. Disruption of a SIRT1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation. Cancer Res. 2011, 71, 964–975.
5. Brooks, C.L.; Gu, W. How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer 2009, 9, 123–128.
6. Liu, T.; Liu, P.Y.; Marshall, G.M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009, 69, 1702–1705.
7. Cha, E.J.; Noh, S.J.; Kwon, K.S.; Kim, C.Y.; Park, B.H.; Park, H.S.; Lee, H.; Chung, M.J.; Kang, M.J.; Lee, D.G. et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin. Cancer Res. 2009, 15, 4453–4459.
8. Lee, H.; Kim, K.R.; Noh, S.J.; Park, H.S.; Kwon, K.S.; Park, B.H.; Jung, S.H.; Youn, H.J.; Lee, B.K.; Chung, M.J. et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum. Pathol. 2011, 42, 204–213.
9. Kim, J.R.; Moon, Y.J.; Kwon, K.S.; Bae, J.S.; Wagle, S.; Yu, T.K.; Kim, K.M.; Park, H.S.; Lee, J.H.; Moon, W.S. et al. Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas. PLoS One 2013, 8, e74738.
10. Kabra, N.; Li, Z.; Chen, L.; Li, B.; Zhang, X.; Wang, C.; Yeatman, T.; Coppola, D.; Chen, J. SIRT1 is an inhibitor of proliferation and tumor formation in colon cancer. J. Biol. Chem. 2009, 284, 18210–18217.
11. Yang, Q.; Wang, B.; Gao, W.; Huang, S.; Liu, Z.; Li, W.; Jia, J. SIRT1 is downregulated in gastric cancer and leads to G1-phase arrest via NF-κB/Cyclin D1 signaling. Mol. Cancer Res. 2013, 11, 1497–1507.
12. Stenzinger, A.; Endris, V.; Klauschen, F.; Sinn, B.; Lorenz, K.; Warth, A.; Goeppert, B.; Ehemann, V.; Muckenhuber, A.; Kamphues, C. et al. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC. Cancer 2013, 13, 450.
13. Huffman, D.M.; Grizzle, W.E.; Bamman, M.M.; Kim, J.S.; Eltoum, I.A.; Elgavish, A.; Nagy, T.R. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007, 67, 6612–6618.
14. Chen, J.; Zhang, B.; Wong, N.; Lo, A.W.; To, K.F.; Chan, A.W.; Ng, M.H.; Ho, C.Y.; Cheng, S.H.; Lai, P.B. et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 2011, 71, 4138–4149.
15. Holloway, K.R.; Barbieri, A.; Malyarchuk, S.; Saxena, M.; Nedeljkovic-Kurepa, A.; Cameron, M.M.; Wang, A.; Gu, X.; Pruitt, K. SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Mol. Endocrinol. 2013, 27, 480–490.
16. Holloway, K.R.; Calhoun, T.N.; Saxena, M.; Metoyer, C.F.; Kandler, E.F.; Rivera, C.A.; Pruitt, K. SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc. Natl. Acad. Sci. USA 2010, 107, 9216–9221.
17. Zhang, Y.; Zhang, M.; Dong, H.; Yong, S.; Li, X.; Olashaw, N.; Kruk, P.A.; Cheng, J.Q.; Bai, W.; Chen, J. et al. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 2008, 28, 445–460.
18. Saxena, M.; Dykes, S.S.; Malyarchuk, S.; Wang, A.E.; Cardelli, J.A.; Pruitt, K. The sirtuins promote Dishevelled-1 scaffolding of TIAM1, Rac activation and cell migration. Oncogene 2013, doi: 10.1038/onc.2013.549.
19. Simmons, G.E., Jr.; Pandey, S.; Nedeljkovic-Kurepa, A.; Saxena, M.; Wang, A.; Pruitt, K. Frizzled 7 expression is positively regulated by SIRT1 and β-catenin in breast cancer cells. PLoS One 2014, 9, e98861.
20. Pruitt, K.; Zinn, R.L.; Ohm, J.E.; McGarvey, K.M.; Kang, S.H.; Watkins, D.N.; Herman, J.G.; Baylin, S.B. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006, 2, e40.
21. Ikenoue, T.; Inoki, K.; Zhao, B.; Guan, K.L. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 2008, 68, 6908–6912.
22. Cornier, M.A.; Dabelea, D.; Hernandez, T.L.; Lindstrom, R.C.; Steig, A.J.; Stob, N.R.; van Pelt, R.E.; Wang, H.; Eckel, R.H. The metabolic syndrome. Endocr. Rev. 2008, 29, 777–822.
23. Zaidi, N.; Lupien, L.; Kuemmerle, N.B.; Kinlaw, W.B.; Swinnen, J.V.; Smans, K. Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids. Prog. Lipid Res. 2013, 52, 585–589.
24. Das, S.K.; Eder, S.; Schauer, S.; Diwoky, C.; Temmel, H.; Guertl, B.; Gorkiewicz, G.; Tamilarasan, K.P.; Kumari, P.; Trauner, M. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011, 333, 233–238.
25. Fearon, K.C.; Glass, D.J.; Guttridge, D.C. Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab. 2012, 16, 153–166.
26. Lee, D.; Goldberg, A.L. SIRT1 protein, by blocking the activities of transcription factors FOXO1 and FOXO3, inhibits muscle atrophy and promotes muscle growth. J. Biol. Chem. 2013, 288, 30515–30526.
27. Makowski, L.; Brittingham, K.C.; Reynolds, J.M.; Suttles, J.; Hotamisligil, G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor γ and IκB kinase activities. J. Biol. Chem. 2005, 280, 12888–12895.
28. Richieri, G.V.; Ogata, R.T.; Zimmerman, A.W.; Veerkamp, J.H.; Kleinfeld, A.M. Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry 2000, 39, 7197–7204.
29. Nieman, K.M.; Kenny, H.A.; Penicka, C.V.; Ladanyi, A.; Buell-Gutbrod, R.; Zillhardt, M.R.; Romero, I.L.; Carey, M.S.; Mills, G.B.; Hotamisligil, G.S. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 2011, 17, 1498–1503.
30. Lee, D.; Wada, K.; Taniguchi, Y.; Al-Shareef, H.; Masuda, T.; Usami, Y.; Aikawa, T.; Okura, M.; Kamisaki, Y.; Kogo, M. Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncol. Rep. 2014, 31, 1116–1120.
31. Uehara, H.; Takahashi, T.; Oha, M.; Ogawa, H.; Izumi, K. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int. J. Cancer 2014, 135, 2558–2568.
32. Walker, A.K.; Yang, F.; Jiang, K.; Ji, J.Y.; Watts, J.L.; Purushotham, A.; Boss, O.; Hirsch, M.L.; Ribich, S.; Smith, J.J. et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 2010, 24, 1403–1417.
33. Haigis, M.C.; Guarente, L.P. Mammalian sirtuin—Emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006, 20, 2913–2921.
34. Pedersen, S.B.; Olholm, J.; Paulsen, S.K.; Bennetzen, M.F.; Richelsen, B. Low Sirt1 expression, which is up-regulated by fasting, in human adipose tissue from obese women. Int. J. Obes. 2008, 32, 1250–1255.
35. Hou, X.; Xu, S.; Maitland-Toolan, K.A.; Sato, K.; Jiang, B.; Ido, Y.; Lan, F.; Walsh, K.; Wierzbicki, M.; Verbeuren, T.J. et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 2008, 283, 20015–20026.
36. Zechner, R.; Kienesberger, P.C.; Haemmerle, G.; Zimmermann, R.; Lass, A. Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. J. Lipid Res. 2009, 50, 3–21.
37. Chakrabarti, P.; English, T.; Karki, S.; Qiang, L.; Tao, R.; Kim, J.; Luo, Z.; Farmer, S.R.; Kandror, K.V. SIRT1 controls lipolysis in adipocytes via FOXO1-mediated expression of ATGL. J. Lipid Res. 2011, 52, 1693–1701.
38. Han, C.Y.; Cho, K.B.; Choi, H.S.; Han, H.K.; Kang, K.W. Role of FOXO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 2008, 29, 1837–1844.
39. Frescas, D.; Valenti, L.; Accili, D. Nuclear trapping of the forkhead transcription factor FOXO1 via SIRT-dependent deacetylation promotes expression of glucogenetic genes. J. Biol. Chem. 2005, 280, 20589–20595.
40. Choi, H.K.; Cho, K.B.; Phuong, N.T.; Han, C.Y.; Han, H.K.; Hien, T.T.; Choi, H.S.; Kang, K.W. SIRT1-mediated FOXO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells. Mol. Pharm. 2013, 10, 2517–2527.
41. Park, J.; Ko, Y.S.; Yoon, J.; Kim, M.A.; Park, J.W.; Kim, W.H.; Choi, Y.; Kim, J.H.; Cheon, Y.; Lee, B.L. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway. Gastric Cancer 2014, 17, 423–430.
42. Wang, X.; Lin, C.; Zhao, X.; Liu, A.; Zhu, J.; Li, X.; Song, L. Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Mol. Cancer 2014, 13, 106.
43. Yang, Y.; Hou, H., Haller, E.M.; Nicosia, S.V.; Bai, W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 2005, 24, 1021–1032.
44. Daitoku, H.; Hatta, M.; Matsuzaki, H.; Aratani, S.; Ohshima, T.; Miyagishi, M.; Nakajima, T.; Fukamizu, A. Silent information regulator 2 potentiates FOXO1-mediated transcription through its deacetylase activity. Proc. Natl. Acad. Sci. USA 2004, 101, 10042–10047.
45. Singh, B.K.; Sinha, R.A.; Zhou, J.; Xie, S.Y.; You, S.H.; Gauthier, K.; Yen, P.M. FOXO1 deacetylation regulates thyroid hormone-induced transcription of key hepatic gluconeogenic genes. J. Biol. Chem. 2013, 288, 30365–30372.
46. Thakran, S.; Sharma, P.; Attia, R.R.; Hori, R.T.; Deng, X.; Elam, M.B.; Park, E.A. Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid hormone. J. Biol. Chem. 2013, 288, 807–818.
47. Farmer, S.R. Regulation of PPAR-γ activity during adipogenesis. Int. J. Obes. 2005, 29, S13–S16.
48. Tontonoz, P.; Hu, E.; Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994, 79, 1147–1156.
49. Barak, Y.; Nelson, M.C.; Ong, E.S.; Jones, Y.Z.; Ruiz-Lozano, P.; Chien, K.R.; Koder, A.; Evans, R.M. PPAR-γ is required for placental, cardiac, and adipose tissue development. Mol. Cell 1999, 4, 585–595.
50. Freytag, S.O.; Paielli, D.L.; Gilbert, J.D. Ectopic expression of the CCAAT/enhancer-binding protein α promotes the adipogenic program in a variety of mouse fibroblastic cells. Genes Dev. 1994, 8, 1654–1663.
51. Tian, L.; Wang, C.; Hagen, F.K.; Gormley, M.; Addya, S.; Soccio, R.; Casimiro, M.C.; Zhou, J.; Powell, M.J.; Xu, P. et al. Acetylation-defective mutant of PPAR-γ is associated with decreased lipid synthesis in breast cancer cells. Oncotarget 2014, 5, 7303–7315.
52. Lin, J.; Handschin, C.; Spiegelman, B.M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005, 1, 361–370.
53. Uldry, M.; Yang, W.; St-Pierre, J.; Lin, J.; Seale, P.; Spiegelman, B.M. Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab. 2006, 3, 333–341.
54. Pilegaard, H.; Neufer, P.D. Transcriptional regulation of pyruvate dehydrogenase kinase 4 in skeletal muscle during and after exercise. Proc. Nutr. Soc. 2004, 63, 221–226.
55. Picard, F.; Kurtev, M.; Chung, N.; Topark-Ngarm, A.; Senawong, T.; de Oliveira, R.M.; Leid, M.; McBurney, M.W.; Guarente, L. SIRT1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature 2004, 429, 771–776.
56. Sugden, M.C.; Caton, P.W.; Holness, M.J. PPAR control: It’s SIRTainly as easy as PGC. J. Endocrinol. 2010, 204, 93–104.
57. Pfluger, P.T.; Herranz, D.; Velasco-Miguel, S.; Serrano, M.; Tschop, M.H. SIRT1 protects against high-fat diet-induced metabolic damage. Proc. Natl. Acad. Sci. USA 2008, 105, 9793–9798.
58. Purushotham, A.; Schug, T.T.; Xu, Q.; Surapureddi, S.; Guo, X.; Li, X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009, 9, 327–338.
59. Xu, F.; Gao, Z.; Zhang, J.; Rivera, C.A.; Yin, J.; Weng, J.; Ye, J. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: A role of lipid mobilization and inflammation. Endocrinology 2010, 151, 2504–2514.
60. Lan, F.; Cacicedo, J.M.; Ruderman, N.; Ido, Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem. 2008, 283, 27628–27635.
61. Armand, V.; Rundfeldt, C.; Heinemann, U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn-Schmiedebergs Arch. Pharmacol. 1999, 359, 33–39.
62. Eberle, D.; Hegarty, B.; Bossard, P.; Ferre, P.; Foufelle, F. SREBP transcription factors: Master regulators of lipid homeostasis. Biochimie 2004, 86, 839–848.
63. Horton, J.D.; Shah, N.A.; Warrington, J.A.; Anderson, N.N.; Park, S.W.; Brown, M.S.; Goldstein, J.L. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 2003, 100, 12027–12032.
64. Shimano, H.; Horton, J.D.; Hammer, R.E.; Shimomura, I.; Brown, M.S.; Goldstein, J.L. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Investig. 1996, 98, 1575–1584.
65. Jiang, T.; Liebman, S.E.; Lucia, M.S.; Phillips, C.L.; Levi, M. Calorie restriction modulates renal expression of sterol regulatory element binding proteins, lipid accumulation, and age-related renal disease. J. Am. Soc. Nephrol. 2005, 16, 2385–2394.
66. Duncan, E.A.; Brown, M.S.; Goldstein, J.L.; Sakai, J. Cleavage site for sterol-regulated protease localized to a Leu-Ser bond in the lumenal loop of sterol regulatory element-binding protein-2. J. Biol. Chem. 1997, 272, 12778–12785.
67. Wang, X.; Sato, R.; Brown, M.S.; Hua, X.; Goldstein, J.L. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 1994, 77, 53–62.
68. Ozawa, H.; Uematsu, T. Peripherally and centrally mediated bradycardiac effects of clonidine in anesthetized or spinal rats. Tohoku J. Exp. Med. 1976, 119, 283–291.
69. Giandomenico, V.; Simonsson, M.; Gronroos, E.; Ericsson, J. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol. Cell. Biol. 2003, 23, 2587–2599.
70. Ponugoti, B.; Kim, D.H.; Xiao, Z.; Smith, Z.; Miao, J.; Zang, M.; Wu, S.Y.; Chiang, C.M.; Veenstra, T.D.; Kemper, J.K. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J. Biol. Chem. 2010, 285, 33959–33970.
71. Hirschey, M.D.; Shimazu, T.; Capra, J.A.; Pollard, K.S.; Verdin, E. SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1,2 and HMGCS1,2. Aging 2011, 3, 635–642.
72. Pavone, M.E.; Bulun, S.E. Aromatase inhibitors for the treatment of endometriosis. Fertil. Steril. 2012, 98, 1370–1379.
73. Johnston, S.R.; Dowsett, M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat. Rev. Cancer 2003, 3, 821–831.
74. Burstein, H.J.; Prestrud, A.A.; Seidenfeld, J.; Anderson, H.; Buchholz, T.A.; Davidson, N.E.; Gelmon, K.E.; Giordano, S.H.; Hudis, C.A.; Malin, J. et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 2010, 28, 3784–3796.
75. Yager, J.D.; Davidson, N.E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 2006, 354, 270–282.
76. Wang, J.; Gildea, J.J.; Yue, W. Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells. Oncogene 2012, 32, 5233–5240.
77. Chetrite, G.S.; Cortes-Prieto, J.; Philippe, J.C.; Wright, F.; Pasqualini, J.R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 2000, 72, 23–27.
78. Geisler, J.; Berntsen, H.; Lonning, P.E. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J. Steroid Biochem. Mol. Biol. 2000, 72, 259–264.
79. Van Landeghem, A.A.; Poortman, J.; Nabuurs, M.; Thijssen, J.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985, 45, 2900–2906.
80. Missmer, S.A.; Eliassen, A.H.; Barbieri, R.L.; Hankinson, S.E. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl. Cancer Inst. 2004, 96, 1856–1865.
81. Kaaks, R.; Rinaldi, S.; Key, T.J.; Berrino, F.; Peeters, P.H.; Biessy, C.; Dossus, L.; Lukanova, A.; Bingham, S.; Khaw, K.T. et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: The European prospective investigation into cancer and nutrition. Endocr. Relat. Cancer 2005, 12, 1071–1082.
82. Key, T.J.; Appleby, P.N.; Reeves, G.K.; Roddam, A.W.; Helzlsouer, K.J.; Alberg, A.J.; Rollison, D.E.; Dorgan, J.F.; Brinton, L.A.; Overvad, K. et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: Reanalysis of 13 studies. Br. J. Cancer 2011, 105, 709–722.
83. Catalano, S.; Barone, I.; Giordano, C.; Rizza, P.; Qi, H.; Gu, G.; Malivindi, R.; Bonofiglio, D.; Ando, S. Rapid estradiol/ERα signaling enhances aromatase enzymatic activity in breast cancer cells. Mol. Endocrinol. 2009, 23, 1634–1645.
84. Yue, W.; Wang, J.P.; Li, Y.; Fan, P.; Liu, G.; Zhang, N.; Conaway, M.; Wang, H.; Korach, K.S.; Bocchinfuso,W. et al. Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. Int. J. Cancer 2010, 127, 1748–1757.
85. Metoyer, C.F.; Pruitt, K. The role of sirtuin proteins in obesity. Pathophysiology 2008, 15, 103–108.
86. Jones, M.E.; Boon, W.C.; Proietto, J.; Simpson, E.R. Of mice and men: The evolving phenotype of aromatase deficiency. Trends Endocrinol. Metab. 2006, 17, 55–64.
87. Bonneterre, J.; Buzdar, A.; Nabholtz, J.M.; Robertson, J.F.R.; Thurlimann, B.; von Euler, M.; Sahmoud, T.; Webster, A.; Steinberg, M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001, 92, 2247–2258.